Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–12.
Article
CAS
PubMed
PubMed Central
Google Scholar
Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of Ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate Cancer. J Clin Oncol. 2017;35(1):40–7.
Article
CAS
PubMed
Google Scholar
Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, et al. PD-L1 is highly expressed in enzalutamide resistant prostate cancer. Oncotarget. 2015;6(1):234–42.
Article
PubMed
Google Scholar
Graff JN, Alumkal JJ, Thompson R, Moran A, Thomas G, Wood M, et al. Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): extended follow up. J Clin Oncol. 2018;36(suppl):abstr 5047.
Article
Google Scholar
Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22(4):813–20.
Article
CAS
PubMed
Google Scholar
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–28.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate Cancer. N Engl J Med. 2016;375(5):443–53.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and Olaparib in metastatic prostate Cancer. N Engl J Med. 2015;373(18):1697–708.
Article
CAS
PubMed
PubMed Central
Google Scholar
De Bono J, Goh J, Ojamaa K, Rodriguez J, Drake CG, Hoimes C, et al. KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2018;36(suppl):abstr 5007.
Article
Google Scholar
Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol. 2018;36(17):1685–94.
Article
PubMed
PubMed Central
Google Scholar
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Barber GN. STING: infection, inflammation and cancer. Nat Rev Immunol. 2015;15(12):760–70.
Article
CAS
PubMed
PubMed Central
Google Scholar
Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7(12):13587–98.
Article
PubMed
PubMed Central
Google Scholar
Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 2015;5(1):16–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, et al. Safety and clinical activity of the programmed death-ligand 1 inhibitor Durvalumab in combination with poly (ADP-ribose) polymerase inhibitor Olaparib or vascular endothelial growth factor receptor 1-3 inhibitor Cediranib in Women's cancers: a dose-escalation, phase I study. J Clin Oncol. 2017;35(19):2193–202.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sittig SP, de Vries IJM, Schreibelt G. Primary human blood dendritic cells for Cancer immunotherapy-tailoring the immune response by dendritic cell maturation. Biomedicine. 2015;3(4):282–303.
CAS
Google Scholar
Lechmann M, Berchtold S, Hauber J, Steinkasserer A. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol. 2002;23(6):273–5.
Article
CAS
PubMed
Google Scholar
Donahue RN, Lepone LM, Grenga I, Jochems C, Fantini M, Madan RA, et al. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. J Immunother Cancer. 2017;5:20.
Article
PubMed
PubMed Central
Google Scholar
Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–30.
Article
CAS
PubMed
Google Scholar
Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A. 2017;114(19):4993–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hartlova A, Erttmann SF, Raffi FA, Schmalz AM, Resch U, Anugula S, et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity. 2015;42(2):332–43.
Article
CAS
PubMed
Google Scholar
Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17(10):1142–9.
Article
CAS
PubMed
Google Scholar
Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714.
Article
CAS
PubMed
Google Scholar
Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, et al. PARP inhibitor upregulates PD-L1 expression and enhances Cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711–20.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8(1):1751.
Article
CAS
PubMed
PubMed Central
Google Scholar
VanderWeele DJ, Finney R, Katayama K, Gillard M, Paner G, Imoto S, et al. Genomic heterogeneity within individual prostate Cancer foci impacts predictive biomarkers of targeted therapy. Eur Urol Focus. 2018; [Epub ahead of print]. https://doi.org/10.1016/j.euf.2018.01.006.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fakhrejahani F, Madan RA, Dahut WL, Karzai FH, Cordes L, Schlom J. Avelumab in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2017;35 (6S)abstr 159.
Article
Google Scholar
Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al. Phase I study of Pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19):4286–93.
Article
CAS
PubMed
Google Scholar
Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7(7):675–93.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wu YM, Cieslik M, Lonigro RJ, Vats P, Reimers MA, Cao X, et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate Cancer. Cell. 2018;173(7):1770–82.e14.
Article
CAS
PubMed
Google Scholar
Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12(4):e1004873.
Article
CAS
PubMed
PubMed Central
Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
Article
CAS
PubMed
Google Scholar
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate Cancer clinical trials working group. J Clin Oncol. 2008;26(7):1148–59.
Article
PubMed
Google Scholar
Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38(1):29–41.
Article
Google Scholar
Kauffman EC, Lee MJ, Alarcon SV, Lee S, Hoang AN, Walton Diaz A, et al. Lack of impact of robotic assisted laparoscopic radical prostatectomy on intraoperative levels of prostate Cancer circulating tumor cells. J Urol. 2016;195(4 Pt 1):1136–42.
Article
PubMed
Google Scholar
Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16(2):177–86.
Article
CAS
PubMed
PubMed Central
Google Scholar
Apolo AB, Karzai FH, Trepel JB, Alarcon S, Lee S, Lee MJ, et al. A phase II clinical trial of TRC105 (anti-Endoglin antibody) in adults with advanced/metastatic urothelial carcinoma. Clin Genitourin Cancer. 2017;15(1):77–85.
Article
PubMed
Google Scholar
Thomas A, Rajan A, Szabo E, Tomita Y, Carter CA, Scepura B, et al. A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. Clin Cancer Res. 2014;20(21):5392–402.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014;15(2):191–200.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tomita Y, Lee MJ, Lee S, Tomita S, Chumsri S, Cruickshank S, et al. The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat. Oncoimmunology. 2016;5(11):e1219008.
Article
CAS
PubMed
PubMed Central
Google Scholar
Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.
Article
CAS
PubMed
Google Scholar
Lepone LM, Donahue RN, Grenga I, Metenou S, Richards J, Heery CR, et al. Analyses of 123 peripheral human immune cell subsets: defining differences with age and between healthy donors and Cancer patients not detected in analysis of standard immune cell types. J Circ Biomark. 2016;5(5);1–17.
Article
CAS
PubMed
PubMed Central
Google Scholar